Another High-Profile Diabetes Candidate Goes Down

Bristol-Myers Squibb' (NYSE: BMY  ) decision to get out of the diabetes drug business is starting to make more and more sense. With Takeda Pharmaceuticals (NASDAQOTH: TKPYY  ) announcing on Friday that it was scrapping its phase 3 drug fasiglifam (or TAK-875, a GPR40 agonist) due to liver toxicity, another potential diabetes blockbuster has disappeared in a puff of smoke.

There are still multiple GLP-1 inhibitors under development and the SGLT1/2 class is about to get started, but Takeda's move leaves precious few innovative diabetes therapies in biotech and Big Pharma pipelines. Between the availability of oral DPP-IV and SGLT-2 inhibitors, (that offer effective glucose control for most people with diabetes), and FDA policies that demand increasingly large and expensive trials for new diabetes medication, more companies may choose to go the route of Bristol-Myers. That is, they may focus their attention on therapeutic areas like oncology.

Takeda goes down
Takeda was absolutely hoping that fasiglifam would help patch the multibillion dollar hole created by the loss of patent coverage on Actos, and there was reason to believe it could be a blockbuster. A prior phase 3 study showed a 0.75 and 1.01 reduction in HbA1c levels at the 25mg and 50mg dosages, results good enough to lead to blockbuster sales. Unfortunately, emerging data from ongoing studies indicated troubling liver toxicity issues and the company had little choice but to terminate the program.


Fasiglifam would have been the first in its class, and there are only a handful of companies I'm aware of that are working on GPR40 drugs -- Indian companies Piramal Healthcare, Advinus, and private company Connexios.

Big Pharma is managing risk/reward
When it comes to other well-known companies with long histories in the diabetes space, the goal today for diabetes drug development appears to be risk/portfolio management. Sanofi (NYSE: SNY  ) and Lilly (NYSE: LLY  ) are working on GLP-1 drugs to join Bristol-Myers/AstraZeneca (NYSE: AZN  ) and Novo Nordisk (NYSE: NVO  ) , and these companies are also working on both longer-acting injectable and oral formulations.

Several companies are also developing SGLT-2 inhibitors, looking to follow in the path laid out by Johnson & Johnson (NYSE: JNJ  ) for what could become another blockbuster class of oral, relatively safe, and effective anti-diabetes agents. Even here, though, there have been challenges tied to the FDA's demand for more rigorous safety studies, and I believe the difficulties in getting Forixga through the FDA loomed large in Bristol-Myers' decision to leave the diabetes space.

Big Pharma is also actively working on various combinations, pairing together existing drugs like DPP-IV inhibitors, GLP-1 agonists, metformin, and others into new branded therapies. While these combinations can give diabetics better control over their disease and added convenience, I would argue the companies' motivations are just as much about maximizing revenue as moving the standard of care forward.

Where's the innovation?
Looking at the pipelines of companies like J&J, Novo Nordisk, and Sanofi, there isn't much in the way of new classes of diabetes therapy under development. I don't mean to denigrate Novo's efforts in an area like oral GLP-1, which would be a solid improvement for patients, but they are not exactly looking for new solutions to the problem.

There are still a handful of new approaches out there. Lilly is working on a glucagon receptor antagonist, and both Amgen (NASDAQ: AMGN  ) and Isis (NASDAQ: ISIS  ) are also exploring the glucagon receptor concept. Smaller companies are working on therapies like glimins, AMPK Activators, and 11-beta HSD1 inhibitors, but larger players have tried some of these before to little effect, and most of these compounds are still in the preclinical or research phase.

The bottom line
There's really no comparison between the pipelines for new oncology drugs and new diabetes drugs around the pharmaceutical and biotech industries. While I'm not arguing that there isn't a very real need for better cancer therapies, it does make me wonder if the state of care today, combined with a much stricter FDA, has effectively disincentivized large companies to invest significant resources in diabetes research. Perhaps all that is needed is for a small biotech to stir up innovation with a new blockbuster, but for now, it looks as though Bristol-Myers isn't the only company taking a break from the diabetes space.

The Motley Fool's Top Stock for 2014

The market stormed out to huge gains across 2013, leaving investors on the sidelines burned. However, opportunistic investors can still find huge winners. The Motley Fool's chief investment officer has just hand-picked one such opportunity in our new report: "The Motley Fool's Top Stock for 2014." To find out which stock it is and read our in-depth report, simply click here. It's free!


Read/Post Comments (2) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 29, 2013, at 7:27 AM, phytodoc wrote:

    The most promising new compound for both prevention and treatment of Type 2 Diabetes is transmax resveratrol. This molecule, which is already being sold as a supplement with FDA blessings, was shown in clinical trials to safely reduce blood glucose and blood pressure levels, up regulate insulin sensitivity, and attenuate LDL serum cholesterol in humans. Three recently published human studies confirm these properties.

  • Report this Comment On January 13, 2014, at 1:48 PM, naturalhealing wrote:

    This week two long awaited new human clinical trial results in which the effect of Transmax Resveratrol as a preventative and adjunct treatment for Type 2 Diabetes were released. What distinguishes these recent human trials is the larger number of subjects tested, the rigid selection criteria used, and the examination of Resveratrol's effects on body weight, blood pressure, cholesterol, and overall health effects in addition to Resveratrol's benefits to the obese and diabetic patients. In these human clinical trials Transmax was shown to have important beneficial action with respect to both prevention of Metabolic Syndrome from evolving into Type 2 Diabetes. Specifically, transmax lowered blood glucose and blood pressure, improved insulin sensitivity, and caused a weight loss in obese patients. Evidence was also presented which confirms that Transmax Resveratrol could attenuate many of the pathologies associated with severe Diabetes, including loss of vision, circulatory problems, and chronic inflammation.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2778155, ~/Articles/ArticleHandler.aspx, 11/22/2014 8:09:48 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement